Compared side by side
Ipamorelin vs GHRP-2: how they differ
The short answer
Both release growth hormone through the ghrelin receptor, and the difference is selectivity: ipamorelin released GH without raising cortisol or ACTH in animal studies, while GHRP-2 is more potent but less selective, so along with GH and IGF-1 it also raises cortisol and prolactin. Both are taken 2–3 times a day. GHRP-2 is approved in Japan only as a diagnostic test for GH deficiency, and ipamorelin was never approved.
Side by side
| Compared | Ipamorelin | GHRP-2 |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | IPAM | Growth Hormone Releasing Peptide-2, Pralmorelin |
| What it is | Considered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides. | A potent growth hormone secretagogue: more potent than Ipamorelin but less selective, so along with GH and IGF-1 it also raises cortisol and prolactin. |
| How it works | Selective growth hormone secretagogue and ghrelin receptor agonist. In animal studies it released GH without raising cortisol or ACTH, and users report milder hunger than with GHRP-6. Considered one of the cleanest GH pulses available. | Potent GH secretagogue that strongly stimulates GH release via ghrelin receptor agonism. More potent than GHRP-6 in animal tests, and users commonly report less appetite stimulation. Also stimulates IGF-1 production. |
| Commonly reported | Deeper sleep and vivid dreams first, then better recovery, skin quality and gradual body-composition changes, with milder hunger than GHRP-6. Its human data are a small GH study and phase 2 trials in surgical patients; it was never approved. | Noticeable hunger after a dose (milder than GHRP-6), a flush or head rush after injecting, and water retention or tingling hands with ongoing use. Approved in Japan only as a diagnostic test for GH deficiency. |
| Studied range | Research range: 200–300 mcg, starting dose 200 mcg. Studied in research — not a recommendation. | Research range: 100–300 mcg. Studied in research — not a recommendation. |
| How often | 2–3x daily, best fasted or before bed | 2–3x daily |
| Half-life | ~2 hours (measured in healthy men, given IV) | ~30 min |
| Route | SubQ injection, IM injection | SubQ injection |
| Typical run | Commonly 8–12 weeks on, 4 weeks off to avoid receptor desensitisation. Some run longer with breaks. | 8–12 weeks. Desensitisation is less rapid than with GHRP-6 or Hexarelin (no head-to-head data), but cycles are still recommended. |
| Evidence | Moderate: animal studies + some human data | Moderate: animal studies + some human data |
| Common side effects | Headache, flushing, nausea, water retention, numbness/tingling | Increased appetite, water retention, fatigue, headache, cortisol/prolactin increase |
- Category
- IpamorelinGrowth hormone
- GHRP-2Growth hormone
- Also known as
- IpamorelinIPAM
- GHRP-2Growth Hormone Releasing Peptide-2, Pralmorelin
- What it is
- IpamorelinConsidered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides.
- GHRP-2A potent growth hormone secretagogue: more potent than Ipamorelin but less selective, so along with GH and IGF-1 it also raises cortisol and prolactin.
- How it works
- IpamorelinSelective growth hormone secretagogue and ghrelin receptor agonist. In animal studies it released GH without raising cortisol or ACTH, and users report milder hunger than with GHRP-6. Considered one of the cleanest GH pulses available.
- GHRP-2Potent GH secretagogue that strongly stimulates GH release via ghrelin receptor agonism. More potent than GHRP-6 in animal tests, and users commonly report less appetite stimulation. Also stimulates IGF-1 production.
- Commonly reported
- IpamorelinDeeper sleep and vivid dreams first, then better recovery, skin quality and gradual body-composition changes, with milder hunger than GHRP-6. Its human data are a small GH study and phase 2 trials in surgical patients; it was never approved.
- GHRP-2Noticeable hunger after a dose (milder than GHRP-6), a flush or head rush after injecting, and water retention or tingling hands with ongoing use. Approved in Japan only as a diagnostic test for GH deficiency.
- Studied range
- IpamorelinResearch range: 200–300 mcg, starting dose 200 mcg. Studied in research — not a recommendation.
- GHRP-2Research range: 100–300 mcg. Studied in research — not a recommendation.
- How often
- Ipamorelin2–3x daily, best fasted or before bed
- GHRP-22–3x daily
- Half-life
- Ipamorelin~2 hours (measured in healthy men, given IV)
- GHRP-2~30 min
- Route
- IpamorelinSubQ injection, IM injection
- GHRP-2SubQ injection
- Typical run
- IpamorelinCommonly 8–12 weeks on, 4 weeks off to avoid receptor desensitisation. Some run longer with breaks.
- GHRP-28–12 weeks. Desensitisation is less rapid than with GHRP-6 or Hexarelin (no head-to-head data), but cycles are still recommended.
- Evidence
- IpamorelinModerate: animal studies + some human data
- GHRP-2Moderate: animal studies + some human data
- Common side effects
- IpamorelinHeadache, flushing, nausea, water retention, numbness/tingling
- GHRP-2Increased appetite, water retention, fatigue, headache, cortisol/prolactin increase
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Ipamorelin
- Day 1–14 Sleep is deepening
- Day 14–28 Recovery is noticeably faster
- Day 28–56 Body composition shifts showing up
- Day 56–84 Cycle-end + planned break
GHRP-2
- Day 1–14 Hits harder than Ipamorelin
- Day 14–56 Recovery and growth are accelerating
Questions people ask
How long do ipamorelin and GHRP-2 last?
The half-life of ipamorelin is ~2 hours (measured in healthy men, given IV). The half-life of GHRP-2 is ~30 min.
How often are ipamorelin and GHRP-2 taken?
Ipamorelin: 2–3x daily, best fasted or before bed. Routes: SubQ injection, IM injection. GHRP-2: 2–3x daily. Route: SubQ injection.
How are ipamorelin and GHRP-2 dosed in research?
The research range for ipamorelin is 200–300 mcg, with a 200 mcg starting dose. The research range for GHRP-2 is 100–300 mcg. Studied in research — not a recommendation.
What are the common side effects of ipamorelin and GHRP-2?
For ipamorelin, the library lists: headache, flushing, nausea, water retention, numbness/tingling. For GHRP-2: increased appetite, water retention, fatigue, headache, cortisol/prolactin increase.